Skip to content

Study Details

Testing the Study Drug TN-201 in Adults with Symptomatic MYBPC3 Mutation-Associated Hypertrophic Cardiomyopathy

(IRB#: IRB_00166206)

Symptomatic MYBPC3 (a gene found in the muscle of the heart) mutation-associated non-obstructive hypertrophic cardiomyopathy is one of the most common inherited cardiac (heart) diseases. This study will test a drug called TN-201 to treat adults with this disease. The study wants to see if the drug will help people with this disease and is safe. The study will have 2 groups of people receiving different doses of the study drug. All participants will receive the study drug. The drug is given as an infusion (liquid drug given under the skin). Being in the study requires meeting in person at a study clinic at different periods of time over 5 years. Participants will receive payment for participation. Medical tests will be done to track the health of participants.


  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 18 to 65 years old
  • Diagnosis of non-obstructive hypertrophic cardiomyopathy
  • Willing to stop drinking alcohol during study participation
  • Able to attend in person at a study clinic

Exclusion Criteria

  • Known allergy to the study drug or any part of the study drug
  • Active infection
  • Scheduled or planning for a major surgery
  • History of hepatitis B or hepatitis C
  • Pregnant

Will I be paid for my time?


For more information contact:

Grecia Gutierrez


IRB#: IRB_00166206

PI: Omar Wever Pinzon


Approval Date: 2024-01-24 07:00:00

Study Categories: Heart Studies

Last Updated: 6/8/23